Country: Malta
Language: English
Source: Medicines Authority
TIROFIBAN
Correvio (UK) Limited
B01AC17
TIROFIBAN
CONCENTRATE FOR SOLUTION FOR INFUSION
TIROFIBAN 4 µg/ml
POM
ANTITHROMBOTIC AGENTS
Authorised
2006-05-29
PACKAGE LEAFLET: INFORMATION FOR THE USER AGGRASTAT (250 MICROGRAMS/ML) CONCENTRATE FOR SOLUTION FOR INFUSION TIROFIBAN READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET: 1. What Aggrastat is and what it is used for 2. What you need to know before you use Aggrastat 3. How to use Aggrastat 4. Possible side effects 5. How to store Aggrastat 6. Contents of the pack and other information 1. WHAT AGGRASTAT IS AND WHAT IT IS USED FOR Aggrastat is used to help assist the blood flow to your heart and to help prevent chest pain and heart attacks. It works by preventing platelets, cells found in the blood, from forming blood clots. This medicine may also be used in patients whose heart vessels are dilated with a balloon (percutaneous coronary intervention or PCI). This is a procedure, possibly with implantation of a small tube (stent), to improve the blood flow to the heart. Aggrastat is intended for use with aspirin and unfractionated heparin. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE AGGRASTAT DO NOT USE AGGRASTAT • if you are allergic (hypersensitive) to tirofiban or any of the other ingredients of Aggrastat (listed in Section 6 “WHAT AGGRASTAT CONTAINS”). • if you are bleeding int Read the complete document
Page 1 of 24 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT AGGRASTAT ®* (50 micrograms/ml) solution for infusion AGGRASTAT ®* (250 micrograms/ml) concentrate for solution for infusion in the following document the abbreviated terms detailed below are used. Aggrastat means Aggrastat solution for infusion or Aggrastat concentrate for solution for infusion. Aggrastat Solution will be used when referring to Aggrastat solution for infusion i.e. the 250 ml bag. Aggrastat Concentrate will be used when referring to Aggrastat concentrate for solution for infusion i.e. the 50 ml vial. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Aggrastat Solution: 1 ml of solution for infusion contains 56 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 50 micrograms tirofiban. Aggrastat Concentrate: 1 ml of concentrate for solution for infusion contains 281 micrograms of tirofiban hydrochloride monohydrate which is equivalent to 250 micrograms tirofiban. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Aggrastat Solution: solution for infusion (250 ml bag). A clear, colourless solution. Aggrastat Concentrate: concentrate for solution for infusion (50 ml vial). A clear, colourless concentrated solution. Page 2 of 24 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Aggrastat is indicated for the prevention of early myocardial infarction in adult patients presenting with acute coronary syndromes without ST elevation (NSTE-ACS) with the last episode of chest pain occurring within 12 hours and with ECG changes and/or elevated cardiac enzymes. Patients most likely to benefit from Aggrastat treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous coronary intervention (PCI). Aggrastat is also indicated for the reduction of atherothombotic events in patients with acute myocardial infarction intended for pri Read the complete document